Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of Apx3330 in Diabetic Retinopathy
Opus Genetics獲得FDA在特殊方案評估下對Apx3330在糖尿病視網膜病瘤第三階段試驗的協議
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of Apx3330 in Diabetic Retinopathy
Opus Genetics獲得FDA在特殊方案評估下對Apx3330在糖尿病視網膜病瘤第三階段試驗的協議
譯文內容由第三人軟體翻譯。
使用瀏覽器的分享功能,分享給你的好友吧